Highest-materiality recent filing
OrthoPediatrics Q2 revenue $70.5M (+15% YoY), raises FY2026 guidance to $265-269M
Q2 2026 revenue $70.5M, up 15% YoY; domestic +14%, international +22%.
OrthoPediatrics Q1 revenue up 13% to $59.4M; lifts FY2026 guidance to $263-267M
Revenue $59.4M (13% YoY); US +11%, International +22%; Trauma & Deformity +14%, Scoliosis +13%.
Record FY2025 revenue $236.3M, up 15% from $204.7M in 2024.
OrthoPediatrics posts record FY2025 revenue $236.1M (+15% YoY); guides FY2026 revenue $262-266M
Q4 2025 revenue $61.3M (+16% YoY); domestic $48.4M (+13%), international $12.9M (+32%).
Revenue $61.2M, +12% YoY (17% ex-7D capital); Trauma & Deformity +17%, Scoliosis +4%.
OrthoPediatrics preliminary Q3 rev $61.2M (+12% YoY); cuts FY guidance to $233.5-$234.5M
Preliminary Q3 net revenue $61.2M, up 12% YoY; domestic $48.7M (+14%), international $12.5M (+6%).
OrthoPediatrics Q2 revenue hits record $61.1M (+16% YoY); raises FY2025 guidance
Revenue of $61.1M (+16% YoY); domestic up 17%, international up 12%.
OrthoPediatrics Q1 revenue $52.4M (+17% YoY); raises FY2025 guidance to $236-242M
Total Q1 revenue $52.4M (+17% YoY); U.S. revenue $40.9M (+19%), international $11.5M (+11%).
Full year 2024 revenue $204.7M, up 38% from $148.7M in 2023; Q4 revenue $52.7M, up 40% YoY.
OrthoPediatrics reports record FY2024 revenue of $204.7M (+38% YoY), issues 2025 guidance
Preliminary unaudited FY2024 revenue $204.7M, up 38% from $148.7M in 2023.
OrthoPediatrics Q3 record revenue $54.6M (+37% YoY); raises FY guidance to $202-204M
Revenue $54.6M (+37% YoY); domestic up 45%, international up 12%.
OrthoPediatrics closes $25M term loan and $50M convertible notes issuance
$25M term loan from Braidwell LP funded on August 12, 2024.
Term loan at SOFR + 6.50% (PIK option adds 1.00%), interest-only until August 2029 maturity.
OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M
Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.
OrthoPediatrics Q1 revenue up 41% to $44.7M; raises FY 2024 guidance to $200-203M
Total revenue $44.7M (+41% YoY); U.S. +44%, international +33%.
OrthoPediatrics FY 2023 revenue $148.7M (+22% YoY); guides FY 2024 rev $197-200M
FY 2023 net loss $21.0M ($0.92/share) vs net income $1.3M ($0.06) in 2022; adjusted EBITDA rose to $5.0M from $0.2M.
Acquired Boston O&P for $22M upfront cash plus ~83,000 restricted shares (~$2.5M) to employees.
OrthoPediatrics prelim Q4 revenue $37.6M (+21%); acquires Boston O&P; 2024 guidance $197-200M
Preliminary Q4 2023 net revenue $37.6M (up 21% YoY); full year $148.7M (up 22%).
OrthoPediatrics enters $80M credit facility with MidCap; $10M term loan drawn
Term loan facility up to $30M (three $10M tranches); first tranche of $10M funded at closing.
OrthoPediatrics reports record Q3 revenue of $40.0M, up 14% YoY; raises adj. EBITDA guidance
Total revenue $40.0M (+14% YoY); U.S. revenue $29.4M (+11%), international $10.6M (+26%).
OrthoPediatrics Q2 revenue $39.6M (+20% YoY); net loss $2.9M, FY guide reaffirmed
Total revenue $39.6M, +20% vs $32.9M in Q2 2022; US +19%, international +25%.
On April 27, 2023, the Board accepted the resignation of Kevin Unger as a member of the Board, which became effective April 28, 2023.
Also effective April 28, 2023, the Board appointed George S. M. Dyer, MD, to fill the vacancy caused by Mr. Unger’s departure and to serve in the class of directors whose terms expire at the annual stockholder meeting in 2023.
Effective October 18, 2022, Stephen F. Burns retired from the OrthoPediatrics Corp. (the “Company”) Board of Directors.
effective October 18, 2022, the Board appointed Jimmy D. McDonald to fill the vacancy caused by Mr. Burns’ retirement to serve in the class of directors whose terms expire at the annual shareholder meeting in 2024.
Effective November 3, 2021, Bernie Berry, III has retired from the Company's Board of Directors after twelve years of service.
The Board has appointed David R. Bailey, the Company’s President and Chief Executive Officer, to fill the vacancy caused by Mr. Berry’s retirement to serve in the Class of Directors whose terms expire at the annual shareholder meeting in 2024.
Max materiality 0.80 · Median 0.35 · Most common event earnings